fda wegovy - Search News

Order byBest matchMost fresh

FDA, Wegovy and Novo Nordisk

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s blockbuster Wegovy medicine to treat a serious fatty liver disease. Shares in Novo Nordisk rose as much as 5% in early European trading Monday,

· 1d · on MSN

Novo Nordisk shares are rising. The FDA approves another use for Wegovy.

Healio · 19h

FDA approves Wegovy for certain adults with noncirrhotic MASH

· 22h

Novo Nordisk's Weight-Loss Drug Wegovy Approved to Treat Liver Disease

He explained that one in three overweight or obese people suffer from it, with some 22 million Americans among them.

· 13h

NVO Stock Up on FDA Nod for Wegovy in MASH: More Upside Ahead?

· 1d

Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease

BioSpace6m

Oral Wegovy’s Pending Approval Puts Spotlight on Viability of High-Dose Peptides

While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured investors it has the manufacturing capacity to roll out oral semaglutide without restrictions on supply.

Zacks.com on MSN53m

NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach beyond obesity and diabetes. NVO-heavy ETFs like OZEM, THNR and PPH should benefit from this trend.

Medscape1d

Wegovy Approved for MASH With Fibrosis, No Cirrhosis

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis but without cirrhosis.